Jane Springer - Hoth Therapeutics VP Operations

HOTH Stock  USD 0.84  0.01  1.20%   

Insider

Jane Springer is VP Operations of Hoth Therapeutics
Age 39
Phone646 756 2997
Webhttps://hoththerapeutics.com

Hoth Therapeutics Management Efficiency

The company has return on total asset (ROA) of (0.4616) % which means that it has lost $0.4616 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8341) %, meaning that it created substantial loss on money invested by shareholders. Hoth Therapeutics' management efficiency ratios could be used to measure how well Hoth Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.
Hoth Therapeutics currently holds 55.16 K in liabilities with Debt to Equity (D/E) ratio of 2.01, implying the company greatly relies on financing operations through barrowing. Hoth Therapeutics has a current ratio of 15.43, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Hoth Therapeutics' use of debt, we should always consider it together with its cash and equity.

Similar Executives

Showing other executives

INSIDER Age

David JinAvenue Therapeutics
34
Tomasz GeorgeVirax Biolabs Group
40
Dr MedScPhio Pharmaceuticals Corp
68
James JDAllarity Therapeutics
55
Matthew ShatzkesAditxt Inc
N/A
Xiaoqin MDAvenue Therapeutics
49
Carol OdleRevelation Biosciences
N/A
Timur DoganCardio Diagnostics Holdings
36
James RolkeRevelation Biosciences
55
Raphael Mechoulam180 Life Sciences
N/A
Jay CrossSonnet Biotherapeutics Holdings
53
Frank KondradNeurobo Pharmaceuticals
N/A
Claus PedersenAllarity Therapeutics
52
Brian StremKiora Pharmaceuticals
44
Jason Assad180 Life Sciences
N/A
MD DrScAllarity Therapeutics
81
MD FACPSonnet Biotherapeutics Holdings
66
Amro AlbannaAditxt Inc
54
Quan Vu180 Life Sciences
52
James FosterVirax Biolabs Group
39
Cameron ShawVirax Biolabs Group
37
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York. Hoth Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people. Hoth Therapeutics (HOTH) is traded on NASDAQ Exchange in USA. It is located in 590 Madison Avenue, New York, NY, United States, 10022 and employs 2 people. Hoth Therapeutics is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Hoth Therapeutics Leadership Team

Elected by the shareholders, the Hoth Therapeutics' board of directors comprises two types of representatives: Hoth Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Hoth. The board's role is to monitor Hoth Therapeutics' management team and ensure that shareholders' interests are well served. Hoth Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Hoth Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Robb Knie, President, Founder
Jane Springer, VP Operations
Hayley Springer, Executive Operations
Stefanie Johns, Chief Officer
David Briones, Chief Officer

Hoth Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Hoth Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Currently Active Assets on Macroaxis

When determining whether Hoth Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Hoth Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Hoth Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Hoth Therapeutics Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Hoth Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For more detail on how to invest in Hoth Stock please use our How to Invest in Hoth Therapeutics guide.
You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Hoth Therapeutics. If investors know Hoth will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Hoth Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Hoth Therapeutics is measured differently than its book value, which is the value of Hoth that is recorded on the company's balance sheet. Investors also form their own opinion of Hoth Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Hoth Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Hoth Therapeutics' market value can be influenced by many factors that don't directly affect Hoth Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Hoth Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Hoth Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Hoth Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.